Literature DB >> 11557787

Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma.

K Sugimachi1, K Taguchi, S Aishima, S Tanaka, M Shimada, K Kajiyama, K Sugimachi1, M Tsuneyoshi.   

Abstract

beta-catenin which has a role in E-cadherin mediated cell-to-cell adhesion, and is also involved in Wnt signaling pathways as a downstream signaling molecule accumulating in the cytoplasm and nucleus constitutively activates Tcf/LEF-associated transcription of oncogenic genes. We examined the expression pattern and the genetic alteration of beta-catenin to determine the role of beta-catenin in cancer formation and/or progression in intrahepatic cholangiocarcinoma (ICC). beta-catenin expression was immunohistochemically examined in 71 surgically resected ICC samples, and correlation between the expression pattern and clinicopathologic factors was investigated. Mutation analysis of beta-catenin exon 3, which included the responsible element for Wnt signaling was done in 55 samples, using PCR-SSCP and direct sequence methods. Immunohistochemical analysis revealed the reduced membranous expression of beta-catenin in 58 (82%) ICCs and aberrant nuclear expression in 11 (15%) ICCs. The membranous expression was preserved in 62% of the papillary adenocarcinomas, and was frequently reduced in tumors with a poorer histological differentiation (84%), with a significant difference (P =.01). Genetic analysis showed that none of the 55 ICCs examined carried mutations in beta-catenin exon 3. The present study indicates that reduced membranous expression of beta-catenin is associated with non-papillary ICCs which have a more malignant behavior, and that nuclear translocation of beta-catenin results in oncogenic events. Mutations in beta-catenin exon 3 do not appear to be responsible for nuclear translocation of beta-catenin in ICCs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557787     DOI: 10.1038/modpathol.3880409

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  37 in total

1.  Interference of suppressor of cytokine signaling 3 promotes epithelial-mesenchymal transition in MHCC97H cells.

Authors:  Yuan-Yuan Ji; Zhi-Dong Wang; Zong-Fang Li; Ke Li
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

2.  Cytoplasmic and/or nuclear accumulation of the beta-catenin protein is a frequent event in human osteosarcoma.

Authors:  Rex C Haydon; Andrea Deyrup; Akira Ishikawa; Robert Heck; Wei Jiang; Lan Zhou; Tao Feng; David King; Hongwei Cheng; Benjamin Breyer; Terrance Peabody; Michael A Simon; Anthony G Montag; Tong-Chuan He
Journal:  Int J Cancer       Date:  2002-12-01       Impact factor: 7.396

Review 3.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

4.  Expression of keratin 20 and its clinicopathological significance in intrahepatic cholangiocarcinoma.

Authors:  Ji Eun Choi; Sang Jae Noh; Ju Hyung Lee; Jun Sang Bae; Hyun Hee Chu; Ho Sung Park; Kyu Yun Jang; Myoung Ja Chung; Myoung Jae Kang; Dong Geun Lee; Woo Sung Moon
Journal:  Oncol Lett       Date:  2012-06-13       Impact factor: 2.967

5.  A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.

Authors:  Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Hepat Oncol       Date:  2014-01-01

6.  Activated macrophages promote Wnt/β-catenin signaling in cholangiocarcinoma cells.

Authors:  Watcharin Loilome; Pornpan Bungkanjana; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Anucha Puapairoj; Narong Khuntikeo; Gregory J Riggins
Journal:  Tumour Biol       Date:  2014-02-19

Review 7.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.

Authors:  D Sia; V Tovar; A Moeini; J M Llovet
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

8.  WTAP regulates migration and invasion of cholangiocarcinoma cells.

Authors:  Hong-Jae Jo; Hye-Eun Shim; Myoung-Eun Han; Hyun-Jung Kim; Ki-Sun Kim; Sungmin Baek; Kyung-Un Choi; Gi-Yeong Hur; Sae-Ock Oh
Journal:  J Gastroenterol       Date:  2013-01-25       Impact factor: 7.527

Review 9.  Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets.

Authors:  Dalbir S Sandhu; Abdirashid M Shire; Lewis R Roberts
Journal:  Liver Int       Date:  2007-11-21       Impact factor: 5.828

10.  Interrelation between expression of matrix metalloproteinase 7 and beta-catenin in esophageal cancer.

Authors:  Hirohi Saeki; Shinji Tanaka; Keishi Sugimachi; Yasue Kimura; Mitsuhiro Miyazaki; Takefumi Ohga; Keizo Sugimachi
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.